Patents by Inventor Ian Cottingham

Ian Cottingham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical preparation
    Patent number: 11952407
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: April 9, 2024
    Assignee: FERRING INTERNATIONAL CENTER S.A.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • PHARMACEUTICAL PREPARATION COMPRISING RECOMBINANT HCG
    Publication number: 20220340634
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Application
    Filed: March 30, 2022
    Publication date: October 27, 2022
    Applicant: Frering B.V.
    Inventors: Ian COTTINGHAM, Daniel PLAKSIN, Rrichard WHITE
  • SELECTIVE IL-6-TRANS-SIGNALLING INHIBITOR COMPOSITIONS
    Publication number: 20220275056
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Application
    Filed: March 9, 2022
    Publication date: September 1, 2022
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • ADMINISTRATION OF A SELECTIVE IL-6-TRANS-SIGNALLING INHIBITOR
    Publication number: 20220135652
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses. Moreover, the inhibitor lessens deleterious effects associated with other IL-6 inhibitors such as lowering neutrophil counts, platelet counts and levels of C-reactive protein.
    Type: Application
    Filed: November 9, 2021
    Publication date: May 5, 2022
    Inventors: Ian Cottingham, Niclas Axel Petri
  • Selective IL-6-trans-signalling inhibitor compositions
    Patent number: 11306136
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: April 19, 2022
    Assignee: Ferring B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • Pharmaceutical preparation comprising recombinant hCG
    Patent number: 11292824
    Abstract: Described are pharmaceutical compositions comprising recombinant human chorionic gonadotropin (hCG) and follicle stimulating hormone (FSH), wherein the recombinant hCG in the composition comprises ?2,3- and ?2,6-sialylation and comprises mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures. The recombinant hCG may be obtained by expression in a human cell line, such as the PER.C6 cell line, optionally wherein the cell line is modified using ?2,3-sialyltransferase.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: April 5, 2022
    Assignee: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard White
  • Methods for treatment of inflammatory disease or IL-6-mediated condition with gp130 protein
    Patent number: 11198721
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses. Moreover, the inhibitor lessens deleterious effects associated with other IL-6 inhibitors such as lowering neutrophil counts, platelet counts and levels of C-reactive protein.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 14, 2021
    Assignee: Ferring B.V.
    Inventors: Ian Cottingham, Niclas Axel Petri
  • PHARMACEUTICAL PREPARATION
    Publication number: 20210332099
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Application
    Filed: April 30, 2021
    Publication date: October 28, 2021
    Applicant: Ferring International Center SA
    Inventors: Ian COTTINGHAM, Daniel PLAKSIN, Richard Boyd WHITE
  • Pharmaceutical preparation
    Patent number: 10995128
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: May 4, 2021
    Assignee: FERRING INTERNATIONAL CENTER SA
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • COMPOSITION FOR CONTROLLED OVARIAN STIMULATION
    Publication number: 20210038694
    Abstract: Compositions including FSH and hCG for use in the treatment of infertility.
    Type: Application
    Filed: April 25, 2019
    Publication date: February 11, 2021
    Applicant: FERRING B.V.
    Inventor: Ian COTTINGHAM
  • PHARMACEUTICAL PREPARATION COMPRISING RECOMBINANT HCG
    Publication number: 20200247863
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Application
    Filed: December 10, 2019
    Publication date: August 6, 2020
    Applicant: Ferring B.V.
    Inventors: Ian COTTINGHAM, Daniel PLAKSIN, Richard WHITE
  • SELECTIVE IL-6-TRANS-SIGNALLING INHIBITOR COMPOSITIONS
    Publication number: 20200123226
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Application
    Filed: November 6, 2019
    Publication date: April 23, 2020
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • Pharmaceutical preparation comprising recombinant HcG
    Patent number: 10526390
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: January 7, 2020
    Assignee: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Selective IL-6-trans-signalling inhibitor compositions
    Patent number: 10519218
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 31, 2019
    Assignee: FERRING B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • SELECTIVE IL-6-TRANS-SIGNALLING INHIBITOR COMPOSITIONS
    Publication number: 20180282396
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
    Type: Application
    Filed: December 1, 2015
    Publication date: October 4, 2018
    Applicant: Ferring B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jérémy Duboeuf
  • PHARMACEUTICAL PREPARATION
    Publication number: 20180079794
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Application
    Filed: August 29, 2017
    Publication date: March 22, 2018
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Pharmaceutical Preparation Comprising Recombinant HcG
    Publication number: 20180030107
    Abstract: The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include ?2,3, ?2,6, and, optionally, ?2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
    Type: Application
    Filed: May 3, 2017
    Publication date: February 1, 2018
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • ADMINISTRATION OF A SELECTIVE IL-6-TRANS-SIGNALLING INHIBITOR
    Publication number: 20170320932
    Abstract: A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses. Moreover, the inhibitor lessens deleterious effects associated with other IL-6 inhibitors such as lowering neutrophil counts, platelet counts and levels of C-reactive protein.
    Type: Application
    Filed: December 1, 2015
    Publication date: November 9, 2017
    Inventors: Ian Cottingham, Niclas Axel Petri
  • Pharmaceutical preparation
    Patent number: 9771407
    Abstract: Preparations including recombinant FSH (rFSH).
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: September 26, 2017
    Assignee: Ferring International Center SA
    Inventors: Ian Cottingham, Daniel Plaksin, Richard Boyd White
  • Pharmaceutical preparation
    Patent number: 9757469
    Abstract: Polyethylene glycol modified human chorionic gonadotropin (hCG), preparations thereof, compositions thereof, and methods of preparation and use thereof are described.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: September 12, 2017
    Assignee: Ferring B.V.
    Inventors: Ian Cottingham, Daniel Plaksin, Jenny Aharanov